A wooden door propped open with a small wedge, daylight spilling into a hallway

You've done it. The weight is off, the blood tests are better, the clothes fit. And then a quieter thought arrives, usually at the pharmacy counter or when a prescription comes up for review: what happens if I stop?

It's one of the most searched questions about these drugs, and for a long time the honest answer was "we think it comes back". We now have three randomised trials that say what actually happens — and that test three different ways out.

What the evidence shows

Exit one: just stop. A 2024 trial called SURMOUNT-4 gave 783 adults with obesity (but not diabetes) tirzepatide — Mounjaro — for 36 weeks (Aronne et al., JAMA, 2024). They lost an average of 20.9% of their body weight. Then 670 of them were randomised, without knowing which, to continue the drug or switch to a placebo injection for another 52 weeks. Those who continued lost a further 5.5%. Those who switched to placebo regained 14.0%. Put another way: 89.5% of people who kept going held on to at least 80% of their weight loss; among those who stopped, 16.6% did. The trial was funded by Eli Lilly, which makes tirzepatide.

Exit two: lower the dose. SURMOUNT-MAINTAIN, published this year, asked a more practical question (Horn et al., The Lancet, 2026). After 60 weeks of tirzepatide at the highest dose they could tolerate, 378 adults with obesity at 20 US sites were randomised to continue that dose, drop to 5 mg, or switch to placebo, for 52 weeks. Nobody knew which they were on. Measured from their original starting weight, people at week 112 were down 21.9% on the full dose, 16.6% on 5 mg, and 9.9% on placebo. There's a telling second number: anyone who regained more than half their lost weight could be "rescued" with tirzepatide. That happened to 8% on the full dose, 25% on the lower dose and 67% on placebo. Lilly-funded again.

Exit three: switch to a tablet. ATTAIN-MAINTAIN took people who had already lost weight on injectable tirzepatide (205 people) or semaglutide — Wegovy — (171 people) and randomised them to a daily tablet, orforglipron, or a placebo tablet, for a year (Aronne et al., Nature Medicine, 2026). Among those who had reached a weight plateau, the tablet preserved an estimated 74.7% of the weight lost on tirzepatide, versus 49.2% on placebo; after semaglutide, 79.3% versus 37.6%. Side effects were mostly mild-to-moderate gut symptoms. Also Lilly-funded — orforglipron is their drug too.

So the shape is consistent across three trials. Stop, and most of the weight returns within a year. Keep going, and it stays off. Lower the dose or switch to a tablet, and you land somewhere in between.

What's still uncertain

The comparison that's missing. ATTAIN-MAINTAIN compared the tablet with nothing. The authors say so themselves: there was no group that simply carried on with the injection. So we don't know whether switching to a tablet is nearly as good as staying on the jab, or a clear step down. That is exactly the question a person at the pharmacy counter is asking.

A year is a year. Every one of these follow-ups stopped at 52 weeks. What the curves do in years two and three — on the tablet, on the lower dose, off everything — is unknown.

Who was studied. These maintenance trials were in people with obesity rather than diabetes. If you take tirzepatide for type 2 diabetes, stopping also affects your blood sugar — the NHS page on tirzepatide puts it plainly: "do not stop suddenly", and your doctor may suggest reducing the dose gradually (NHS).

The quiet good news. In both tirzepatide trials, the people who stopped were still about 10% below their original weight a year later. Stopping isn't back to square one. It's back to roughly half-way.

One funder. All three trials were paid for by the company that makes the drugs. That's normal for drug trials, and the designs were sound — but independent replication would be welcome.

What you can do

If you're thinking about stopping — for cost, supply or any other reason — make it a planned decision, not a lapsed prescription. The one action: before anything changes, write down your current weight and your latest blood results, so you and your doctor have a baseline to compare against. Then the question: "If I need to come off this, what are my options — a lower dose, a different drug, a plan for the regain — and how will we know if it's working?"

These drugs don't cure anything. They hold a door open while you're taking them. Knowing that in advance isn't a reason for despair — it's the difference between a decision and a surprise.

— Dr. Brugal

Weight that comes back is a theme we keep returning to: Why fasting weight comes back so fast: water vs fat · Why fasting results fade: the 18-month problem · The new diabetes treatments — what is real in 2026, and what is coming. · Managing diabetes every day: what the evidence actually says matters.

References

All studies retrieved via PubMed.

  1. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. Randomised withdrawal trial, 670 people with obesity (no diabetes) randomised after 36 weeks of tirzepatide, 52 weeks double-blind. doi:10.1001/jama.2023.24945 (PMID 38078870)
  2. Horn DB, Aronne LJ, Wharton S, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. 2026;407(10545):2305-2318. Double-blind randomised trial, 378 people with obesity randomised after 60 weeks of tirzepatide, 52 weeks. doi:10.1016/S0140-6736(26)00656-2 (PMID 42119587)
  3. Aronne LJ, Horn DB, le Roux CW, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nature Medicine. 2026;32(7):2679-2687. Double-blind placebo-controlled randomised trial, 376 people previously treated with tirzepatide (205) or semaglutide (171), 52 weeks. doi:10.1038/s41591-026-04386-7 (PMID 42120723)

Awareness content — not medical advice. Always talk to your doctor or pharmacist before making changes.